Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/120651
Title: | Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours |
Author: | Zurita, A. J. Diestra, J. E. Condom i Mundó, Enric García del Muro Solans, Xavier Scheffer, G. L. Scheper, R. J. Pérez, J. Germà Lluch, José Ramón Izquierdo, M. A. |
Keywords: | Malalties del testicle Cèl·lules germinals Tumors Expressió gènica Proteïnes supressores de tumors Resistència als medicaments Testis diseases Germ cells Tumors Gene expression Tumor suppressor protein Drug resistance |
Issue Date: | 24-Mar-2003 |
Publisher: | Cancer Research UK |
Abstract: | This study was undertaken to investigate the expression and predictive value for outcome of multidrug resistance-associated (MDR) proteins P-glycoprotein (Pgp), MRP1, BCRP, and LRP, in advanced testicular germ-cell tumours (TGCT). Paraffin-embedded sections from 56 previously untreated patients with metastatic TGCT were immunostained for Pgp, MRP1, BCRP, and LRP. All patients received platinum-based chemotherapy after orchidectomy. Immunostaining was related to clinicopathological parameters, response to chemotherapy, and outcome. Strong and intermediate expressions of the different MDR-related proteins were: 27 and 41% (Pgp), 54 and 37% (MRP1), 86 and 7% (BCRP), and 14 and 29% (LRP). P-glycoprotein and MRP1 associated, respectively, to low AFP (P=0.026) and high LDH levels (P=0.014), whereas LRP expression associated with high β-hCG levels (P=0.003) and stage IV tumours (P=0.029). No correlation was found between Pgp, MRP1, and BCRP expression and response to chemotherapy and survival. In contrast, patients with LRP-positive tumours (strong or intermediate expression) had shorter progression-free (P=0.0006) and overall survival (P=0.0116) than LRP-negative patients, even after individual log-rank adjustments by statistically associated variables. Our data suggest that a positive LRP immunostaining at the time of diagnosis in metastatic TGCT is associated with an adverse clinical outcome. |
Note: | Reproducció del document publicat a: https://doi.org/10.1038/sj.bjc.6600803 |
It is part of: | British Journal of Cancer, 2003, vol. 88, num. 6, p. 879-886 |
URI: | http://hdl.handle.net/2445/120651 |
Related resource: | https://doi.org/10.1038/sj.bjc.6600803 |
ISSN: | 0007-0920 |
Appears in Collections: | Articles publicats en revistes (Patologia i Terapèutica Experimental) Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
524876.pdf | 197.12 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License